Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients.
Orazio CaffoViviana FrantellizziFabio MonariAndrea SbranaRenato Patrizio CostaCarmine PintoMarcello TucciSergio BaldariGaetano FacchiniRoberto BortolusFilippo AlongiPierpaolo AlongiAntonio PalermoStefano FantiElisa BiascoAlessandra MurabitoAngelina FiliceClizia ZichiSalvatore PignataEugenio BorsattiMatteo SalgarelloMassimiliano SpadaEnrico CortesiGiuseppe De VincentisPublished in: Future oncology (London, England) (2021)
Background: Radium 223 (RA223) is currently administered as part of a therapeutic sequence with the other life-prolonging agents (LPAs) for metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: We retrospectively reviewed the clinical records of patients who had received at least three LPAs including RA223. Results: Median overall survival (OS) from the start of first-line treatment was 39.8 months, with the patients who completed all six planned courses of RA223 having a longer OS than those who did not (53.2 vs 29.5 months; p < 0.0001). Conclusions: Our study confirms the activity of RA223 regardless of the treatment line in which it is administered and suggests that patient selection plays a central role in maximizing this activity.
Keyphrases
- end stage renal disease
- rheumatoid arthritis
- ejection fraction
- newly diagnosed
- chronic kidney disease
- disease activity
- small cell lung cancer
- squamous cell carcinoma
- prognostic factors
- peritoneal dialysis
- ankylosing spondylitis
- single cell
- patient reported outcomes
- systemic lupus erythematosus
- systemic sclerosis
- smoking cessation
- combination therapy
- idiopathic pulmonary fibrosis